Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses

被引:104
作者
Work, LM
Büning, H
Hunt, E
Nicklin, SA
Denby, L
Britton, N
Leike, K
Odenthal, M
Drebber, U
Hallek, M
Baker, AH
机构
[1] Univ Glasgow, Div Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland
[2] Univ Cologne, Internal Med Clin 1, D-50924 Cologne, Germany
[3] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[4] Univ Glasgow, Dept Comp Sci, Bioinformat Res Ctr, Glasgow G12 8QQ, Lanark, Scotland
基金
英国医学研究理事会;
关键词
adeno-associated virus; phage display; endothelium; rat; targeting; systemic delivery;
D O I
10.1016/j.ymthe.2005.11.013
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Virus-mediated gene delivery is restricted by the infectivity profile of the chosen vector. Targeting the vascular endothelium via systemic delivery has been attempted using pepticles isolated in vitro (using either phage or vector display) and implicit reliance on target receptor expression in vivo. This has limited application since endothelial cells in vitro and in vivo differ vastly in receptor profiles and because of the existence of complex endothelial "zip codes" in vivo. We therefore tested whether in vivo phage display combined with adeno-associated virus (AAV) capsid modifications would allow in vivo homing to the endothelium residing in defined organs. Extensive in vivo biopanning in rats identified four consensus pepticles homing to the lung or brain. Each was incorporated into the VP3 region of the AAV-2 capsid to display the peptide at the virion surface. Peptides that conferred heparan independence were shown to retarget virus to the expected vascular bed in vivo in a preferential manner, determined 28 days post-systemic injection by both virion DNA and transgene expression profiling. Our findings significantly impact the design of viral vectors for targeting individual vascular beds in vivo.
引用
收藏
页码:683 / 693
页数:11
相关论文
共 39 条
[1]   The Renaissance rat [J].
Abbott, A .
NATURE, 2004, 428 (6982) :464-466
[2]  
Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkw1099, 10.1093/nar/gkh131]
[3]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[4]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[5]   Targeting the prostate for destruction through a vascular address [J].
Arap, W ;
Haedicke, W ;
Bernasconi, M ;
Kain, R ;
Rajotte, D ;
Krajewski, S ;
Ellerby, HM ;
Bredesen, DE ;
Pasqualini, R ;
Ruoslahti, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1527-1531
[6]   Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation [J].
Denby, L ;
Nicklin, SA ;
Baker, AH .
GENE THERAPY, 2005, 12 (20) :1534-1538
[7]   Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy [J].
Dishart, KL ;
Denby, L ;
George, SJ ;
Nicklin, SA ;
Yendluri, S ;
Tuerk, MJ ;
Kelley, MP ;
Donahue, BA ;
Newby, AC ;
Harding, T ;
Baker, AH .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (07) :739-748
[8]   Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture [J].
Durr, E ;
Yu, JY ;
Krasinska, KM ;
Carver, LA ;
Yates, JR ;
Testa, JE ;
Oh, P ;
Schnitzer, JE .
NATURE BIOTECHNOLOGY, 2004, 22 (08) :985-992
[9]   Anti-cancer activity of targeted pro-apoptotic peptides [J].
Ellerby, HM ;
Arap, W ;
Ellerby, LM ;
Kain, R ;
Andrusiak, R ;
Del Rio, G ;
Krajewski, S ;
Lombardo, CR ;
Rao, R ;
Ruoslahti, E ;
Bredesen, DE ;
Pasqualini, R .
NATURE MEDICINE, 1999, 5 (09) :1032-1038
[10]   Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 [J].
Girod, A ;
Ried, M ;
Wobus, C ;
Lahm, H ;
Leike, K ;
Kleinschmidt, J ;
Deléage, G ;
Hallek, M .
NATURE MEDICINE, 1999, 5 (09) :1052-1056